Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to -$54000.0.

  • Rocket Pharmaceuticals' Capital Expenditures fell 10340.05% to -$54000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $669000.0, marking a year-over-year decrease of 9344.12%. This contributed to the annual value of $5.9 million for FY2024, which is 6433.44% down from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Capital Expenditures stood at -$54000.0, which was down 10340.05% from $50000.0 recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Capital Expenditures registered a high of $4.7 million during Q3 2023, and its lowest value of -$54000.0 during Q3 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' median Capital Expenditures value was $2.0 million (recorded in 2022), while the average stood at $2.0 million.
  • Per our database at Business Quant, Rocket Pharmaceuticals' Capital Expenditures skyrocketed by 251055.9% in 2021 and then crashed by 10340.05% in 2025.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Capital Expenditures stood at $2.0 million in 2021, then soared by 52.82% to $3.0 million in 2022, then skyrocketed by 54.75% to $4.6 million in 2023, then crashed by 93.35% to $309000.0 in 2024, then plummeted by 117.48% to -$54000.0 in 2025.
  • Its Capital Expenditures stands at -$54000.0 for Q3 2025, versus $50000.0 for Q2 2025 and $364000.0 for Q1 2025.